Výsledky vyhledávání - "Donald A. Fitch"

Two Randomized Trials of Linaclotide for Chronic Constipation

Autor: James Z. Shao, Caroline B. Kurtz, Paul Eng, Jeffrey M. Johnston, James E. MacDougall, Harvey Schneier, Bernard J. Lavins, S J Shiff, Susan M. Fox, Donald A. Fitch, Brenda I. Jeglinski, Mark G. Currie, Xinwei D. Jia, Anthony Lembo

Publikováno v: New England Journal of Medicine. 365:527-536

Linaclotide is a minimally absorbed peptide agonist of the guanylate cyclase C receptor. In two trials, we aimed to determine the efficacy and safety of linaclotide in patients with chronic constipation.We conducted two randomized, 12-week, multicent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7435dba23ba7e3629168ae98b8149a8
https://doi.org/10.1056/nejmoa1010863

Zobrazit plný text záznamu

Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety

Autor: Caroline B. Kurtz, William D. Chey, Anthony Lembo, Xinwei D. Jia, Mark G. Currie, Jeffrey M. Johnston, Mollie J. Baird, Harvey Schneier, James Z. Shao, Bernard J. Lavins, S J Shiff, James E. MacDougall, Donald A. Fitch

Publikováno v: The American journal of gastroenterology. 107(11)

Linaclotide is a minimally absorbed peptide guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide treatment in patients with irritable bowel syndrome with constipation (IBS-C) over 26 weeks.T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2129ef4046b2e69321c425aa0399da91
https://pubmed.ncbi.nlm.nih.gov/23791794

Zobrazit plný text záznamu

Tu1381 Effects of 26 Weeks of Linaclotide Treatment on Adequate Relief and IBS Severity in Patients With Irritable Bowel Syndrome With Constipation

Autor: William D. Chey, Xinming Hao, Bernard J. Lavins, Kelvin Shi, Donald A. Fitch, Mollie J. Baird, Jeffrey M. Johnston, Eamonn Martin Quigley, Harvey Schneier, Mark G. Currie

Publikováno v: Gastroenterology. 142:S-817

Introduction There have been few long-term studies evaluating treatments for IBS. Linaclotide (LIN), a 14 amino acid, minimally absorbed, guanylate cyclase C agonist (GCCA), was evaluated in 2 Phase 3 trials in patients (pts) with IBS-C, including a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::39ae1674003699256908f3f20c688148
https://doi.org/10.1016/s0016-5085(12)63175-8

Zobrazit plný text záznamu

Linaclotide Improves Abdominal Pain and Bowel Habits in a Phase IIb Study of Patients With Irritable Bowel Syndrome With Constipation

Autor: Bernard J. Lavins, Anthony Lembo, Mollie J. Baird, Caroline B. Kurtz, Donald A. Fitch, Mark G. Currie, Jeffrey M. Johnston, Chris O'Dea, James E. MacDougall

Publikováno v: Gastroenterology. 139:1877-1886.e2

Background & Aims Linaclotide, a minimally absorbed, 14-amino acid peptide agonist of guanylate cyclase-C, has shown benefit in a proof-of-concept study for the treatment of patients with irritable bowel syndrome (IBS) with constipation (IBS-C). We a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d229f48fca639642391ff79c9d599e9
https://doi.org/10.1053/j.gastro.2010.08.041

Zobrazit plný text záznamu

Efficacy of Linaclotide for Patients With Chronic Constipation

Autor: Jeffrey M. Johnston, Brenda I. Jeglinski, Caroline B. Kurtz, Mark G. Currie, Donald A. Fitch, Bernard J. Lavins, James E. MacDougall, Anthony Lembo

Publikováno v: Gastroenterology. 138:886-895.e1

Background & Aims Linaclotide is a minimally absorbed peptide agonist of the guanylate cyclase-C receptor that stimulates intestinal fluid secretion and transit and reduces pain in animal models. We assessed the safety and efficacy of a range of lina

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::64959096fe213178ab8aefa9bd15dd69
https://doi.org/10.1053/j.gastro.2009.12.050

Zobrazit plný text záznamu

Incidence of Latent Hepatic Diseases in Blood Donors: Possible Relation to Carrier State of Viral Hepatitis

Autor: Richard K. Watanabe, Robert F. Norris, Dicran Kassouny, John G. Reinhold, Donald R. Fitch, John R. Neefe

Publikováno v: American Journal of Clinical Pathology. 25:158-165

That viral hepatitis may be transmitted by whole blood or plasma is well known. The assumption has often been made that persons suffering from clinically inapparent infection are transient carriers of the virus and are infectious for only short perio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e63e792bf766cb039dd4ec7b567a120e
https://doi.org/10.1093/ajcp/25.2.158

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání